MA46586A - Compositions de terlipressine et leurs procédés d'utilisation - Google Patents

Compositions de terlipressine et leurs procédés d'utilisation

Info

Publication number
MA46586A
MA46586A MA046586A MA46586A MA46586A MA 46586 A MA46586 A MA 46586A MA 046586 A MA046586 A MA 046586A MA 46586 A MA46586 A MA 46586A MA 46586 A MA46586 A MA 46586A
Authority
MA
Morocco
Prior art keywords
methods
terlipressin
compositions
terlipressin compositions
Prior art date
Application number
MA046586A
Other languages
English (en)
Inventor
Gary Patou
Original Assignee
Chiasma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiasma Inc filed Critical Chiasma Inc
Publication of MA46586A publication Critical patent/MA46586A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1816Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891Coated capsules; Multilayered drug free capsule shells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
MA046586A 2016-10-21 2017-10-20 Compositions de terlipressine et leurs procédés d'utilisation MA46586A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662410971P 2016-10-21 2016-10-21
US201762472291P 2017-03-16 2017-03-16

Publications (1)

Publication Number Publication Date
MA46586A true MA46586A (fr) 2019-08-28

Family

ID=62019439

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046586A MA46586A (fr) 2016-10-21 2017-10-20 Compositions de terlipressine et leurs procédés d'utilisation

Country Status (10)

Country Link
US (3) US10993984B2 (fr)
EP (2) EP3528828B1 (fr)
JP (3) JP2020500164A (fr)
AU (2) AU2017345720B2 (fr)
CA (1) CA3037581A1 (fr)
ES (1) ES3023754T3 (fr)
IL (2) IL265761B2 (fr)
MA (1) MA46586A (fr)
WO (1) WO2018075897A1 (fr)
ZA (1) ZA201901912B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ591810A (en) 2008-09-17 2012-12-21 Chiasma Inc Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
PL3253401T3 (pl) 2015-02-03 2025-08-04 Amryt Endo, Inc. Leczenie akromegalii oktreotydem doustnym
CN109223720B (zh) * 2018-09-12 2020-11-27 南京康舟医药科技有限公司 注射用醋酸特利加压素冻干粉针剂的制备方法
WO2021127234A2 (fr) * 2019-12-20 2021-06-24 Northwestern University Conjugué terlipressine-acide octadécanedioïque pour traitement vasoconstricteur
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
CN114306250B (zh) * 2021-11-26 2023-07-14 苏州天马医药集团天吉生物制药有限公司 一种醋酸特利加压素制剂及其制备方法
US20240156895A1 (en) * 2022-10-28 2024-05-16 Mallinckrodt Pharmaceuticals Ireland Limited Compositions for improving kidney function in patients with hepatorenal syndrome

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH455823A (de) 1964-08-01 1968-05-15 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von Peptiden
EP1188443A1 (fr) 2000-09-15 2002-03-20 Ferring BV Protocole amélioré pour la paracentèse
JO2937B1 (en) 2004-08-11 2016-03-15 فيرينغ.بي.في Tight muscles of the peptide vascular tensioner receptor
AU2007215406B2 (en) 2006-02-10 2011-12-08 Ferring B.V Novel compounds
GB2438834A (en) 2006-06-08 2007-12-12 Optinose As Intranasal protein administration
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
AU2015201581B2 (en) * 2008-09-17 2017-03-09 Amryt Endo, Inc. Pharmaceutical Compositions and Related Methods of Delivery
NZ591810A (en) * 2008-09-17 2012-12-21 Chiasma Inc Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
WO2011116139A2 (fr) * 2010-03-16 2011-09-22 Chiasma Inc. Compositions pharmaceutiques améliorées et procédés d'administration
WO2014165607A2 (fr) * 2013-04-02 2014-10-09 Stealth Peptides International, Inc. Formulations peptidiques cationiques aromatiques, compositions et procédés d'utilisation
JO3371B1 (ar) 2013-07-26 2019-03-13 Ferring Bv ناهضات مستقبل فاسوبريسين 2
HRP20220225T1 (hr) 2014-10-24 2022-04-29 Mallinckrodt Pharmaceuticals Ireland Limited Terlipresin za liječenje hepatorenalnog sindroma tip 1
US10500248B2 (en) 2015-03-30 2019-12-10 Sunnybrook Research Institute Method for treating cancer
JP2017014206A (ja) 2015-06-30 2017-01-19 ナノアンティバイオティクス,インコーポレイテッド 腹水の治療

Also Published As

Publication number Publication date
EP3528828A1 (fr) 2019-08-28
EP4516803A2 (fr) 2025-03-05
IL265761A (en) 2019-06-30
AU2023255036A1 (en) 2023-11-16
ZA201901912B (en) 2023-10-25
IL313083A (en) 2024-07-01
EP4516803A3 (fr) 2025-06-25
JP2020500164A (ja) 2020-01-09
IL265761B2 (en) 2024-11-01
US20250000933A1 (en) 2025-01-02
ES3023754T3 (en) 2025-06-03
CA3037581A1 (fr) 2018-04-26
WO2018075897A1 (fr) 2018-04-26
US10993984B2 (en) 2021-05-04
US20220313773A1 (en) 2022-10-06
AU2017345720B2 (en) 2023-07-27
JP2025020319A (ja) 2025-02-12
NZ751717A (en) 2025-05-02
EP3528828B1 (fr) 2025-01-29
EP3528828A4 (fr) 2020-07-01
AU2017345720A1 (en) 2019-04-11
JP2023120445A (ja) 2023-08-29
IL265761B1 (en) 2024-07-01
US20190240284A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
EP3704239A4 (fr) Compositions de casz et procédés d'utilisation
EP3630199A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3630788A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3630789A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3436048A4 (fr) Néoantigènes et leurs procédés d'utilisation
EP3435956A4 (fr) Compositions photo-stabilisées et leurs procédés d'utilisation
EP3414321A4 (fr) Compositions améliorant vcn et procédés d'utilisation desdites compositions
MA46566A (fr) Oxystérols et leurs procédés d'utilisation
MA46565A (fr) Oxystérols et leurs procédés d'utilisation
EP3307762A4 (fr) Variants de cas9 rapporteurs et leurs procédés d'utilisation
EP3684364A4 (fr) Pyridazinones et leurs procédés d'utilisation
EP3352774A4 (fr) Compositions de flavonoïdes et procédés d'utilisation
MA55097A (fr) Oxystérols et leurs procédés d'utilisation
EP3341017A4 (fr) Compositions d'immunomodulation et leurs procédés d'utilisation
MA41999A (fr) Compositions d'acide obéticholique et procédés d'utilisation
EP3390624A4 (fr) Polypeptides de modification ciblée modifiés et leurs procédés d'utilisation
EP3436061A4 (fr) Compositions de conjugués saccharide-polypeptide polymérisables et leurs procédés d'utilisation
EP3416634A4 (fr) Agents immunomodulateurs et leurs procédés d'utilisation
EP3377615A4 (fr) Compositions d'induction d'haploïdes et procédés d'utilisation associés
EP3319610A4 (fr) Oxystérols et leurs procédés d'utilisation
EP3319612A4 (fr) Oxystérols et leurs procédés d'utilisation
EP3298168A4 (fr) Agents réducteurs stabilisés et leurs procédés d'utilisation
EP3303634A4 (fr) Variants de cas9 et procédés d'utilisation associés
EP3394065A4 (fr) Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés
EP3337823A4 (fr) Compositions de support-agent de liaison et leurs procédés de fabrication et d'utilisation